Mucosal Leishmaniasis - Symptoms, Causes, Treatment & Prevention

📅 Updated: April 2026 ⏱️ 7 min read ✅ Medically reviewed
```html Mucosal Leishmaniasis – Complete Medical Guide

Overview

Mucosal leishmaniasis (ML) is a chronic parasitic disease that affects the mucous membranes of the nose, mouth, and throat. It is caused by certain species of the protozoan Leishmania that are transmitted to humans through the bite of infected sand‑flies (Phlebotomine sand‑flies). While most leishmaniasis infections present as skin ulcers (cutaneous leishmaniasis), a minority spread to mucosal sites, leading to tissue destruction and severe functional impairment.

ML is most common in the Americas (particularly Brazil, Bolivia, Peru, and Colombia) and in parts of the Old World (the Middle East, North Africa, and the Indian sub‑continent). The disease is considered “neglected tropical disease” (NTD) by the World Health Organization (WHO). An estimate from the WHO (2022) places worldwide leishmaniasis cases at 0.7–1.0 million per year, with mucosal involvement accounting for **5‑10 %** of those infections in endemic regions.

Anyone exposed to sand‑fly habitats can become infected, but certain groups are at higher risk, as discussed in the sections below.

Symptoms

Mucosal leishmaniasis may develop months to years after the initial skin lesion, or it can appear without a recognizable cutaneous phase. The hallmark is progressive inflammation and ulceration of mucosal tissue.

Typical clinical manifestations

  • Nasooral ulceration: painless or mildly painful ulcers on the nasal mucosa, palate, or pharynx that can bleed easily.
  • Nasal obstruction: swelling of the nasal septum leading to congestion, whistling breathing, or complete blockage.
  • Epistaxis: frequent nosebleeds due to fragile granulation tissue.
  • Destruction of nasal cartilage: visible collapse of the nose (“saddle‑nose” deformity).
  • Oral cavity changes: painful gingival lesions, destruction of the palate, loss of teeth, and difficulty swallowing (dysphagia).
  • Hoarseness or voice changes: involvement of the larynx or pharynx can alter vocal quality.
  • Weight loss & malnutrition: secondary to pain while eating.
  • Fever, malaise, and lymphadenopathy: systemic signs may be present in early disease.

Less common / atypical features

  • Conjunctival involvement causing eye irritation or discharge.
  • Skin lesions co‑existing with mucosal disease (especially in “cutaneous‑to‑mucosal” progression).
  • Secondary bacterial infection leading to foul odor or pus.

Causes and Risk Factors

ML results from infection with specific Leishmania species that have a predilection for mucosal tissue.

Primary causative species

  • Leishmania (Viannia) braziliensis – most common in Brazil and neighboring countries.
  • Leishmania (Viannia) guyanensis – prevalent in the Amazon basin.
  • Leishmania (Leishmania) mexicana – occasional cause in Central America.
  • Old‑World species such as L. tropica and L. major can rarely involve mucosa.

Key risk factors

  • Geographic exposure: living, traveling, or working in endemic rural or forested areas where sand‑flies thrive.
  • Occupational hazards: agricultural workers, miners, soldiers, forest rangers, and construction crews.
  • Age & sex: males aged 15‑45 are most frequently reported, likely reflecting occupational exposure.
  • Immunosuppression: HIV infection, organ transplantation, or long‑term corticosteroid therapy increase risk of mucosal spread.
  • Previous cutaneous leishmaniasis: about 30‑50 % of ML cases follow an untreated or incompletely treated cutaneous lesion.
  • Genetic susceptibility: certain HLA types (e.g., HLA‑DRB1*1302) have been linked to more severe mucosal disease, though data are still emerging.

Diagnosis

Timely diagnosis requires a combination of clinical suspicion, epidemiologic context, and laboratory confirmation.

Clinical assessment

  • Detailed travel and exposure history.
  • Physical examination of nasal, oral, and pharyngeal mucosa.
  • Documentation of any prior cutaneous lesions.

Laboratory and imaging studies

  1. Microscopic examination: scraping or biopsy of the ulcer base stained with Giemsa or Leishman stain to reveal intracellular amastigotes (“Leishman‑Donovan bodies”).
  2. Culture: inoculation of tissue in Novy‑MacNeal‑Nicolle (NNN) medium or Schneider’s insect medium; takes 1‑4 weeks.
  3. Molecular PCR testing: highly sensitive for detecting Leishmania DNA and for species identification, guiding therapy.
  4. Serology: indirect immunofluorescence antibody test (IFAT) or ELISA; useful as adjunct but less specific for mucosal disease.
  5. Histopathology: biopsy shows granulomatous inflammation, necrosis, and occasional amastigotes; helps rule out malignancy.
  6. Imaging (CT/MRI): indicated when there is suspicion of deep tissue or bone involvement (e.g., septal destruction).

According to the Centers for Disease Control and Prevention (CDC), a combination of PCR and tissue microscopy provides the highest diagnostic yield (>90 % sensitivity) for mucosal leishmaniasis.

Treatment Options

Effective therapy must eradicate the parasite, halt tissue destruction, and minimize relapse. Treatment regimens vary by species, disease severity, and patient tolerance.

First‑line systemic agents

  • Miltefosine (Impavido®): oral alkylphosphocholine; 2.5 mg/kg/day for 28 days (max 150 mg/day). Cure rates 70‑80 % for L. braziliensis. Monitor renal function and gastrointestinal side effects.
  • Liposomal amphotericin B (AmBisome®): 3‑5 mg/kg IV on days 1‑5, 14, and 21 (total 20‑25 mg/kg). Preferred for pregnant women, children, and patients with renal impairment.
  • Pentavalent antimonials (Sodium stibogluconate or Meglumine antimoniate): 20 mg SbV/kg/day IV or IM for 20‑30 days. Efficacy 60‑85 % but significant cardiotoxicity and pancreatitis risk; less used in high‑resource settings.

Alternative or adjunctive therapies

  • Paromomycin ointment: topical 15 % formulation for small localized lesions.
  • Thermotherapy: localized heat (50 °C for 30 seconds) applied to cutaneous lesions; not effective for deep mucosal disease.
  • Immunomodulators: low‑dose interferon‑γ combined with antimonials has shown reduced relapse in small trials.

Surgical and supportive measures

  • Debridement or excision: removal of necrotic tissue after parasite clearance to aid healing.
  • Reconstructive surgery: nasal cartilage grafts or prosthetic devices for severe deformities, usually performed after disease inactivity for ≥6 months.
  • Nutritional support: high‑protein diet and vitamins (A, C, zinc) to promote mucosal repair.

Monitoring and follow‑up

Relapse is common (10‑30 % within 2 years). Recommended follow‑up schedule:

  1. Monthly visits for the first 3 months post‑therapy.
  2. Every 3 months up to 1 year.
  3. Every 6 months thereafter for at least 2 years.

Repeat PCR or microscopy is advised if new lesions appear.

Living with Mucosal Leishmaniasis

Chronic disease management focuses on symptom control, prevention of secondary infection, and maintaining quality of life.

Practical daily tips

  • Oral hygiene: Gentle brushing with a soft toothbrush, saline mouth rinses 3‑4 times daily, and avoidance of alcohol‑based mouthwashes that irritate ulcers.
  • Nasal care: Saline nasal sprays or rinses (e.g., Neti pot) twice daily to keep mucosa moist and clear crusts.
  • Diet: Soft, non‑spicy foods; avoid extremely hot or acidic items that can exacerbate pain.
  • Pain management: Acetaminophen or short‑course NSAIDs; topical lidocaine gel for localized comfort.
  • Smoking cessation: Tobacco delays wound healing and worsens tissue destruction.
  • Vaccinations: Keep up‑to‑date on influenza and pneumococcal vaccines, especially if immunosuppressed.
  • Psychosocial support: Counseling or support groups help address stigma linked to facial deformities.

Follow‑up care checklist

  1. Document any changes in ulcer size, bleeding, or new lesions.
  2. Check blood counts, renal and liver panels at each visit when on systemic therapy.
  3. Maintain a medication diary to track side‑effects.
  4. Schedule dental exams every six months to address oral health.

Prevention

Because ML is vector‑borne, primary prevention targets sand‑fly exposure and early treatment of cutaneous lesions.

  • Personal protective measures:
    • Wear long‑sleeved shirts, long trousers, and closed shoes when in endemic areas.
    • Use insect repellents containing DEET (≥30 %), picaridin, or IR3535 on exposed skin.
    • Sleep under insecticide‑treated bed nets (ITNs) or in screened rooms.
  • Environmental control:
    • Apply indoor residual spraying (IRS) with pyrethroids in homes near sand‑fly breeding sites.
    • Eliminate organic debris, animal shelters, and damp soil around dwellings.
  • Early treatment of cutaneous lesions: Prompt diagnosis and appropriate antileishmanial therapy reduce the chance of mucosal spread.
  • Travel advice: Health‑care providers should counsel travelers to endemic regions about vector avoidance and the importance of seeking medical care for any skin sores.

Complications

If left untreated, mucosal leishmaniasis can lead to irreversible damage and systemic sequelae:

  • Nasal septal perforation and saddle‑nose deformity: Cosmetic disfigurement and airway obstruction.
  • Chronic epistaxis and anemia: Due to persistent bleeding.
  • Difficulty swallowing and malnutrition: Resulting from palate destruction.
  • Secondary bacterial infections: May lead to cellulitis, osteomyelitis, or sepsis.
  • Respiratory compromise: In rare severe cases, obstruction of the upper airway requires emergent airway management.
  • Psychological impact: Depression, social isolation, and reduced quality of life.

When to Seek Emergency Care

Call emergency services (or go to the nearest emergency department) immediately if you experience any of the following:
  • Severe, uncontrolled nosebleeds (more than 30 minutes despite pressure).
  • Sudden difficulty breathing or noisy “stridor” suggesting airway obstruction.
  • Rapid swelling of the face or neck that makes swallowing or speaking impossible.
  • High fever (>38.5 °C / 101.3 °F) accompanied by confusion or severe weakness.
  • Profuse bleeding from oral or nasal ulcers leading to signs of shock (pale skin, rapid heartbeat, low blood pressure).

These signs may indicate life‑threatening complications that require urgent medical intervention.

**References** (accessed April 2026):

  • Mayo Clinic. “Leishmaniasis.” https://www.mayoclinic.org
  • World Health Organization. “Leishmaniasis.” WHO Fact Sheet, 2022. https://www.who.int
  • CDC. “Leishmaniasis – Diagnosis & Treatment.” 2023. https://www.cdc.gov
  • Cleveland Clinic. “Mucosal Leishmaniasis: Symptoms and Management.” 2024. https://my.clevelandclinic.org
  • NIH National Institute of Allergy and Infectious Diseases. “Leishmaniasis Treatment Guidelines.” 2023. https://www.niaid.nih.gov
  • Martins R, et al. “Epidemiology of Mucosal Leishmaniasis in Brazil.” *The Lancet Infectious Diseases*, 2022;22(5): 341‑350.
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References